IRC
ASBPW

Investors Research Corp’s Aspire Biopharma Warrant ASBPW Stock Holding History

Investors Research Corp’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
10
– – ﹤0.01% 899
2026
Q1 		$0 Hold
10
– – ﹤0.01% 953
2025
Q4 		$0 Hold
10
– – ﹤0.01% 908
2025
Q3 		$0 Hold
10
– – ﹤0.01% 953
2025
Q2 		$0 Buy
+10
New – ﹤0.01% 978
2025
Q1 		– Sell
-10
Closed – – 996
2024
Q4 		$0 Hold
10
– – ﹤0.01% 993
2024
Q3 		$0 Hold
10
– – ﹤0.01% 1066
2024
Q2 		$0 Hold
10
– – ﹤0.01% 1099
2024
Q1 		$0 Hold
10
– – ﹤0.01% 1101
2023
Q4 		$1 Hold
10
– – ﹤0.01% 1063
2023
Q3 		$1 Hold
10
– – ﹤0.01% 1074
2023
Q2 		$1 Hold
10
– – ﹤0.01% 1086
2023
Q1 		$0 Hold
10
– – ﹤0.01% 1160
2022
Q4 		$1 Hold
10
– – ﹤0.01% 1140
2022
Q3 		$0 Hold
10
– – ﹤0.01% 1144
2022
Q2 		$0 Buy
+10
New +$2 ﹤0.01% 1161

Other funds holding ASBPW

CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Investors Research Corp's ASBPW Position: Q2 2026 in Review

Investors Research Corp held its Aspire Biopharma Warrant (ASBPW) position steady in Q2 2026 at 10 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #899.

Investors Research Corp first reported a position in ASBPW in Q2 2022 and has held it in 16 quarters since. The position peaked at $1 in Q4 2023. 2 funds tracked by Wall St. Rank hold ASBPW as of Q2 2026.

  • Investors Research Corp held 10 shares of Aspire Biopharma Warrant worth $0 as of Q2 2026.
  • Investors Research Corp left its Aspire Biopharma Warrant share count unchanged in Q2 2026.
  • Aspire Biopharma Warrant made up ﹤0.01% of Investors Research Corp's portfolio in Q2 2026, its #899 holding.
  • Investors Research Corp first reported a position in Aspire Biopharma Warrant in Q2 2022 and has held it in 16 quarters since.
  • Investors Research Corp's Aspire Biopharma Warrant position peaked at $1 in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2026.

Based on Investors Research Corp's 13F filing for Q2 2026, filed 10 Jul 2026.